

VPA22020/016/004

ATOPICA 100 mg soft capsules for dogs

Variation	Summary	Date
Vet - B11 b)	VNRA - Vet - B11 b) - b) Tightening of specification limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance - B11 b) Changes to the quality part of the dossier: Change in the specification parameters or limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance or of the immediate packaging of the active substance — tightening of specification limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance	30/11/23
Vet - B11 b)	VNRA - Vet - B11 b) - b) Tightening of specification limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance - B11 b) Changes to the quality part of the dossier: Change in the specification parameters or limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance or of the immediate packaging of the active substance — tightening of specification limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance	30/11/23
Vet - B11 b)	VNRA - Vet - B11 b) - b) Tightening of specification limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance - B11 b) Changes to the quality part of the dossier: Change in the specification parameters or limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance or of the immediate packaging of the active substance — tightening of specification limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance	30/11/23
Vet - B11 b)	VNRA - Vet - B11 b) - b) Tightening of specification limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance - B11 b) Changes to the quality part of the dossier: Change in the specification parameters or limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance or of the immediate packaging of the active substance — tightening of specification limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance	30/11/23
Vet - B47 b)	VNRA - Vet - B47 b) - b) Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State - B47 b) Changes to the quality part of the dossier: Change to comply with Ph. Eur. or with a national	18/10/23

	pharmacopoeia of a Member State: — change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State	
Vet - A1 b)	VNRA - Vet - A1 b) - b) Change in the name or address or contact details of a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance or a quality control testing site (where ecified in the dossier) where no European Pharmacopoeia (Ph. Eur.) Certificate of Suitability (CEP) is part of the approved dossier. - A1 b) Administratvie changes: Change in the name or address or contact details of a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance or a quality control testing site (where ecified in the dossier) where no European Pharmacopoeia (Ph. Eur.) Certificate of Suitability (CEP) is part of the approved dossier.	19/09/23
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	04/05/23
Vet - B12 a)	VNRA - Vet - B12 a) - a) Minor changes to an approved test procedure (active, finished product, packaging, measuirng device) - B12 a) Changes to the quality part of the dossier: Minor changes — to an approved test procedure — for active substance; — for the finished product; —for the immediate packaging of the active substance or the finished product; — of a measuring or administration device	25/04/23
Vet - C4	VNRA - Vet - C4 - Change(s) in the SPC, labelling or package leaflet intended to implement the outcome of a procedure or recommendation from the competent authority or the Agency concerning risk management measures in pharmacovigilance related to veterinary medicinal products - C4 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the SPC, labelling or package leaflet intended to implement the outcome of a procedure or recommendation from the competent authority or the Agency concerning risk management measures in pharmacovigilance related to veterinary medicinal products	29/03/23
Vet - B12 a)	VNRA - Vet - B12 a) - a) Minor changes to an approved test	29/03/23

	<p>procedure (active, finished product, packaging, measuring device)</p> <p>- B12 a) Changes to the quality part of the dossier: Minor changes — to an approved test procedure — for active substance; — for the finished product; —for the immediate packaging of the active substance or the finished product; — of a measuring or administration device</p>	
Vet - B45	<p>VNRA - Vet - B45 - Submission of a new Ph. Eur. CEP from a new manufacturer (replacement or addition) for a non-sterile active substance, starting material, reagent or intermediate, excipient - B45 Changes to the quality part of the dossier: Submission of a new Ph. Eur. CEP from a new manufacturer (replacement or addition) for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient</p>	29/03/23
Vet - F.I.d.1 c)	<p>VRA-R - Vet - F.I.d.1 c) - c) Extension or introduction of a re-test period/storage period supported by real time data - F.I.d.1 c) Quality Changes - Active Substance - Stability -Change in the re-test period/storage period of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - Extension or introduction of a re-test period/storage period supported by real time data</p>	09/01/23
A.4	<p>IA - A.4 - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - A.4 - ADMINISTRATIVE CHANGES - Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier)</p>	11/02/22